Clinical Trials Logo

Overall Response Rate clinical trials

View clinical trials related to Overall Response Rate.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06277024 Recruiting - Clinical trials for Overall Response Rate

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients